MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.6% in premarket trading on Friday despite the company reporting ...
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer ...
— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita ...
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or ...
Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved clinically meaningful reductions in blood Phe levels at month one of the open-label ...
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Almost half of women of reproductive age experience complaints in the days leading up to menstruation. A lot of treatments come with side effects, only provide limited relief, or don't work for ...
Please provide your email address to receive an email when new articles are posted on . The blood test aims to predict lupus flares and drug targets rapidly by analyzing RNA gene expression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results